CE IVD recomBead Luminex® Assays

Luminex^® multiplex technology: the benefits

• Fast: 20 minutes sample incubation, 20 minutes conjugate incubation. Analysis result in less than 3 hours
• High-throughput assay: ideal test for high sample throughput
• Automation with Dynablot: fully automated processing and evaluation possible. Connection to the laboratory information system (LIS) possible
• Precise: very high measurement accuracy and reproducibility of the test results
• All in one: the detection of antibodies against individual antigens combines the advantages of ELISA and confirmatory tests
• Low sample volume: 10 μl is sufficient for serum, plasma and CSF
• Flexible combination: different parameters and conjugate classes on one plate possible with same incubation times
• Safety thanks to integrated controls: incubation control, conjugate control, negative control

Luminex^® multiplex technology: test principle

Colour-coded differentiation of up to 100 different bead populations, specific simultaneous analysis of up to 100 parameters in one sample possible. Utilisation of magnetic polystyrene beads (MagPlex^®) for the highest recovery rate.

1. Antibody detection with recomBead tests

• Multianalyte assays based on immunodominant, diagnostically relevant antigens.
• Addition of patient serum to the bead mix provided: bound antibodies are labelled with a specific detection antibody (conjugate).
• The antigen-antibody complexes are analysed and the results are clearly displayed on the analyser. The different colouring assigns the beads to their respective population/antigen, the fluorescence intensity results from the amount of bound antibodies.

2. CXCL13 Sandwich technology

• Anti-hCXCL13: covalent binding to the magnetic beads. The quantification of the target antigen CXCL13 in the CSF sample is carried out using a sandwich assay with anti-hCXCL13 antibodies and a biotinstreptavidin reporter system.

recomBead portfolio

recomBead Borrelia IgG, IgM 2.0

• Simultaneous but separate detection of individual antigen-specific antibodies – classification into early and late phase of Borrelia infection possible
• Species-specific p18 (Dbpa) antigens of the 5 predominant Borrelia species: B. b. sensu strictu, B. garinii, B. afzelii, B. spielmanii, B. bavariensis – optimal setting for the typing of Borrelia bacteria
• Possibility of quantitative determination of VlsE exists (research use only)
• Serum and cerebrospinal fluid diagnostics with determination of the Borrelia-specific antibody index (AI)
• Small sample volume (10 μl) is sufficient – particularly important in CSF diagnostics

recomBead CXCL13 PART A and PART B

• CXCL13: Activity marker for acute neuroborreliosis and other inflammatory diseases of the central diseases of the central nervous system
• Detection of CXCL13/BLC (BLC = B lymphocyte chemoattractant) in human cerebrospinal fluid
• Quantification of CXCL13 antigens to be detected using integrated standard curves

recomBead EBV IgG, IgM 2.

• Reliable detection of past infections with the Epstein-Barr virus due to very high EBNA-1 specificity – the key antigen in EBV serology
• Reliable detection of acute infections due to the very high sensitivity of early antigens
• Simultaneous, separate detection of all relevant EBV antigens
  

recomBead Yersinia IgG, IgA 2.0

• Screening or confirmation test using recombinant Yersinia antigens: Yersinia enterocolitica and Yersinia pseudotuberculosis
• Detection of all human pathogenic Yersinia using the Yersinia Outer Proteins (YOPs)
• Differentiation between Y. enterocolitica and Y. pseudotuberculosis infection serologically possible for the first time through the use of new species-specific Yersinia antigens (PsaA, MyfA)
• No cross-reactions to Brucella and other pathogens, and no interference from LPS

recomBead Treponema IgG, IgM 2.0

• Reliable detection using immunodominant, recombinant antigens
• Use of the highly specific, minimally cross-reactive treponema antigens Tp47, Tp17, Tp15 and TmpA as well as Tp257 (Gpd) and Tp453
• Can be used as a confirmatory assay for positive or unclear samples form screening